HK1251462A1 - 微泡複合物及使用方法 - Google Patents
微泡複合物及使用方法Info
- Publication number
- HK1251462A1 HK1251462A1 HK18110916.0A HK18110916A HK1251462A1 HK 1251462 A1 HK1251462 A1 HK 1251462A1 HK 18110916 A HK18110916 A HK 18110916A HK 1251462 A1 HK1251462 A1 HK 1251462A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- microbubble complexes
- microbubble
- complexes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201113235890A | 2011-09-19 | 2011-09-19 | |
US13/528,399 US20130072854A1 (en) | 2011-09-19 | 2012-06-20 | Microbubble complexes and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1251462A1 true HK1251462A1 (zh) | 2019-02-01 |
Family
ID=46852013
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15101059.9A HK1200362A1 (zh) | 2011-09-19 | 2015-02-02 | 微泡複合物及使用方法 |
HK18110916.0A HK1251462A1 (zh) | 2011-09-19 | 2018-08-24 | 微泡複合物及使用方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15101059.9A HK1200362A1 (zh) | 2011-09-19 | 2015-02-02 | 微泡複合物及使用方法 |
Country Status (13)
Country | Link |
---|---|
US (3) | US20130072854A1 (zh) |
EP (1) | EP2758081B1 (zh) |
JP (1) | JP6059725B2 (zh) |
KR (1) | KR20140063697A (zh) |
CN (2) | CN103957940B (zh) |
AU (1) | AU2012311659B2 (zh) |
BR (1) | BR112014006412A2 (zh) |
CA (1) | CA2849037A1 (zh) |
ES (1) | ES2621821T3 (zh) |
HK (2) | HK1200362A1 (zh) |
MX (1) | MX347719B (zh) |
RU (1) | RU2613321C2 (zh) |
WO (1) | WO2013041500A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10136835B1 (en) | 2012-05-02 | 2018-11-27 | University Of Washington Through Its Center For Commercialization | Determining a presence of an object |
US9743909B1 (en) * | 2013-05-15 | 2017-08-29 | University Of Washington Through Its Center For Commercialization | Imaging bubbles in a medium |
KR20150034517A (ko) | 2013-09-26 | 2015-04-03 | 삼성전자주식회사 | 소수성 활성 성분 및 폴리펩티드의 복합체를 포함하는 리포좀, 및 그의 용도 |
US10052394B2 (en) * | 2014-11-21 | 2018-08-21 | General Electric Company | Microbubble tether for diagnostic and therapeutic applications |
GB201511459D0 (en) * | 2015-06-30 | 2015-08-12 | Cell Therapy Ltd | Sirna microbubble |
GB201520649D0 (en) * | 2015-11-23 | 2016-01-06 | Univ Ulster | Sonodynamic therapy |
KR102245539B1 (ko) * | 2018-02-12 | 2021-04-29 | 주식회사 지앤피바이오사이언스 | 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물 |
KR102398743B1 (ko) * | 2020-09-03 | 2022-05-16 | 충남대학교병원 | 초음파유도 마이크로버블을 포함하는 배뇨장애 치료제 조성물 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO940711D0 (no) | 1994-03-01 | 1994-03-01 | Nycomed Imaging As | Preparation of gas-filled microcapsules and contrasts agents for diagnostic imaging |
US6521211B1 (en) * | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
JP4774135B2 (ja) * | 1996-03-12 | 2011-09-14 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 標的された部位特異的薬物送達組成物およびその使用 |
DE69724599T2 (de) * | 1996-03-12 | 2004-08-05 | The Board Of Regents Of The University Of Nebraska, Lincoln | Zusammensetzung zur zielortspezifischen verabreichung eines medikamentes und verfahren zur anwendung |
US8137684B2 (en) * | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
AU733495B2 (en) * | 1996-10-28 | 2001-05-17 | Nycomed Imaging As | Improvements in or relating to diagnostic/therapeutic agents |
HUP0000357A2 (hu) * | 1996-10-28 | 2000-06-28 | Nycomed Imaging A/S | Továbbfejlesztett diagnosztikai/terápiás szerek |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
JPH111811A (ja) | 1997-06-05 | 1999-01-06 | Aderans Co Ltd | かつら用ストッパー及びかつら用ストッパー取付け用シート |
WO2000042988A1 (en) * | 1999-01-21 | 2000-07-27 | University Of Virginia | Method of identifying and treating inflamed tissue |
AU3366901A (en) * | 1999-12-30 | 2001-07-16 | Novartis Ag | Novel colloid synthetic vectors for gene therapy |
CA2425508A1 (en) * | 2000-10-11 | 2002-04-18 | John S. Pease | Targeted therapeutic agents |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
EP1319423A3 (en) * | 2001-12-11 | 2003-10-08 | Dornier Medtech System GmbH | Apparatus and method for initiating chemical reactions and for the targeted delivery of drugs or other agents |
AU2002241270A1 (en) * | 2002-03-22 | 2003-10-08 | Anges Mg, Inc. | Compositions for delivering biologically active drug and method of using the same |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
EP1644479A4 (en) * | 2003-06-16 | 2008-04-23 | Mark W Grinstaff | MACROMOLECULES AND FUNCTIONAL SYNTHETIC MOLECULES FOR GENES ADMINISTRATION |
EP1644475A4 (en) | 2003-06-20 | 2009-06-03 | Isis Pharmaceuticals Inc | DOUBLE-STRAND COMPOSITIONS WITH A 3'-ENDO-MODIFIED STRING FOR USE IN GENE MODULATION |
JP2005314381A (ja) * | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
CA2591582A1 (en) * | 2004-12-17 | 2006-06-22 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
US7893244B2 (en) | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
JP4992071B2 (ja) * | 2005-07-29 | 2012-08-08 | 国立大学法人 鹿児島大学 | 眼球組織への生理活性薬剤導入のための組成物及び装置 |
CN100551440C (zh) * | 2006-08-30 | 2009-10-21 | 中国人民解放军第三军医大学第二附属医院 | 一种用于肿瘤超声治疗的治疗型超声微泡及其制备方法 |
GB0621973D0 (en) * | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
US20080114287A1 (en) | 2006-11-14 | 2008-05-15 | Kar Neng Lai | Ultrasound Microbubble Mediated Genes Delivery System |
US20080311045A1 (en) * | 2007-06-06 | 2008-12-18 | Biovaluation & Analysis, Inc. | Polymersomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo |
CA2702028A1 (en) | 2007-10-02 | 2009-04-09 | Rxi Pharmaceuticals Corp. | Tripartite rnai constructs |
KR101198354B1 (ko) | 2007-10-17 | 2013-03-14 | 주식회사 삼양바이오팜 | 핵산 전달용 저밀도 지단백질 유사(LDL-like) 양이온성 나노입자, 그의 제조방법 및 이를 이용한 핵산의 전달 방법 |
BRPI0704944A8 (pt) | 2007-11-30 | 2017-08-15 | V & M Do Brasil S/A | Eixo forjado de tubo sem costura para veículos ferroviários e processo de fabricação de eixo forjado de tubo sem costura para veículos ferroviários |
-
2012
- 2012-06-20 US US13/528,399 patent/US20130072854A1/en not_active Abandoned
- 2012-09-18 RU RU2014108245A patent/RU2613321C2/ru not_active IP Right Cessation
- 2012-09-18 WO PCT/EP2012/068288 patent/WO2013041500A1/en active Application Filing
- 2012-09-18 ES ES12759459.6T patent/ES2621821T3/es active Active
- 2012-09-18 EP EP12759459.6A patent/EP2758081B1/en active Active
- 2012-09-18 CN CN201280045451.6A patent/CN103957940B/zh active Active
- 2012-09-18 BR BR112014006412A patent/BR112014006412A2/pt not_active IP Right Cessation
- 2012-09-18 JP JP2014530263A patent/JP6059725B2/ja active Active
- 2012-09-18 KR KR1020147006830A patent/KR20140063697A/ko not_active Application Discontinuation
- 2012-09-18 CN CN201710959069.0A patent/CN107737335B/zh active Active
- 2012-09-18 CA CA2849037A patent/CA2849037A1/en not_active Abandoned
- 2012-09-18 MX MX2014003358A patent/MX347719B/es active IP Right Grant
- 2012-09-18 AU AU2012311659A patent/AU2012311659B2/en not_active Ceased
-
2015
- 2015-02-02 HK HK15101059.9A patent/HK1200362A1/zh not_active IP Right Cessation
-
2016
- 2016-07-26 US US15/219,419 patent/US10004760B2/en active Active
-
2018
- 2018-06-25 US US16/016,963 patent/US11007212B2/en active Active
- 2018-08-24 HK HK18110916.0A patent/HK1251462A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN103957940A (zh) | 2014-07-30 |
WO2013041500A1 (en) | 2013-03-28 |
HK1200362A1 (zh) | 2015-08-07 |
US20130072854A1 (en) | 2013-03-21 |
JP2014526493A (ja) | 2014-10-06 |
KR20140063697A (ko) | 2014-05-27 |
US11007212B2 (en) | 2021-05-18 |
ES2621821T3 (es) | 2017-07-05 |
CA2849037A1 (en) | 2013-03-28 |
RU2613321C2 (ru) | 2017-03-15 |
US10004760B2 (en) | 2018-06-26 |
RU2014108245A (ru) | 2015-10-27 |
US20190060347A1 (en) | 2019-02-28 |
MX347719B (es) | 2017-05-10 |
CN103957940B (zh) | 2017-11-17 |
BR112014006412A2 (pt) | 2017-04-04 |
EP2758081A1 (en) | 2014-07-30 |
CN107737335A (zh) | 2018-02-27 |
MX2014003358A (es) | 2014-08-01 |
AU2012311659B2 (en) | 2017-06-15 |
EP2758081B1 (en) | 2017-02-08 |
US20170007636A1 (en) | 2017-01-12 |
AU2012311659A1 (en) | 2014-04-10 |
CN107737335B (zh) | 2023-08-29 |
JP6059725B2 (ja) | 2017-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181628T1 (hr) | Spojevi i postupci za njihovu upotrebu | |
HK1243417A1 (zh) | 吡啶酮和氮雜吡啶酮化合物及使用方法 | |
HK1255608A1 (zh) | 抗htra1抗體及使用方法 | |
HK1208439A1 (zh) | -氮雜吲唑化合物及其使用方法 | |
IL227440B (en) | Spherical support device and methods of use | |
HK1251462A1 (zh) | 微泡複合物及使用方法 | |
EP2685882A4 (en) | FABRIC TRACTOR AND METHOD FOR ITS USE | |
IL222227A0 (en) | Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use | |
EP2912178A4 (en) | SUPER AMPLIFIER AND METHOD FOR USE THEREOF | |
EP2751270A4 (en) | OLIGOMER CONJUGATE COMPLEXES AND ITS USE | |
ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
EP2675471A4 (en) | HSA-RELATED COMPOSITIONS AND USE PROCESSES | |
HK1201843A1 (zh) | 抗聚泛素抗體及使用方法 | |
EP2834421A4 (en) | STABILIZING AGENTS AND METHODS OF USE | |
EP2928384A4 (en) | ANCHORS CAPTURED BY THE FABRIC AND METHOD OF USE | |
EP2790709A4 (en) | HEMOSTATIC ACTIVE SUBSTANCES AND METHOD OF USE THEREOF | |
EP2852397A4 (en) | HUWENTOXIN IV VARIANTS AND METHODS OF USE | |
HK1194308A1 (zh) | 雙功能酶制鉗型分子的方法和用途 | |
EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
EP2710384A4 (en) | DIAGNOSIS AND TREATMENT OF COPD | |
ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
EP2753359A4 (en) | SERPINF2 BINDEMOLEKÜLE AND METHOD FOR THEIR USE | |
HK1202853A1 (zh) | 觸變劑和使用方法 | |
EP2776462A4 (en) | INDOLALKYLAMINO WITHASTEROID CONJUGATES AND USE METHOD THEREFOR |